We help you join the dots...

RAS LSS is a niche strategy consultancy serving the global life sciences sector


Starting with Information Services in 2014, RAS LSS has evolved into a boutique healthcare consulting group. We offer a niche portfolio of Strategy Support and Information Services to Pharmaceutical and Medical Device Companies, throughout the product life-cycle.

We elucidate and contextualize current and future market complexities. Leveraging our collective intelligence, we strive to help our clients succeed via

  • Best In Class Situation Analysis
  • Competitively Differentiated Strategy
With an outreach across mature and emerging markets, we go the extra mile to create fresh perspectives for our clients in their mission to reduce the global burden of disease.

We have put in the hours and the sweat to be credible…

Latest Blogs

April 14, 2017

China – Drug Approval Reform

China’s Food and Drug Administration has started implementing key reforms that are likely to be a game changer for pharma companies eyeing the Chinese market.  The presentation below highlights the key reforms:     Key Takeaways: Leveling of Phase 1 playing field: Pharma companies can run a phase 1 trial […]
April 12, 2017
Operational Challenges in Biosim

Operational Challenge in Biosimilar Development

A biosimilar product is essentially a non-inferior ‘twin’ of the reference biologic with similar clinical efficacy and safety. Biosimilar development is a fairly new and evolving landscape with many unique operational challenges. This blog explores some of these challenges and ways to overcome the barriers. The regulatory approval requires biosimilar […]
April 3, 2017
Interchangeable Biosimilars

Interchangeable biosimilars

Finally, FDA has come out with its interchangeability guidelines.  The US drug regulatory agency has presented its recommendations for the data requirement for a biologic product to be interchangeable to a reference product. You may go through the draft guidance upon following the link. As per the FDA guidelines, an […]
April 3, 2017
Combating biosimilars

Combating biosimilars – Rituxan

The Oncologic Drugs Advisory Committee (ODAC) of FDA has unanimously recommended approval of subcutaneous (SC) rituximab for the treatment of patients with certain blood cancers. A final approval to this effect is expected by June 26, 2017 (Official Announcement). The approval of SC formulation certainly has its benefits such as, […]
March 31, 2017
Biosim go to market strategy

Biosimilar go-to-market strategy

Commercialization is the next frontier for biosimilar developers. As more and more biosimilars are gaining regulatory approvals, the discussion on commercial aspects of the yet evolving market is gaining momentum. Biosimilar commercialization will have its very specific attributes and nuances. Biosimilars are neither first- nor best- in class products, these […]
December 26, 2016

Exhibitors at ESMO

65 big/small/medium Pharmaceutical companies and 10 publishers took part in the ESMO. A white based theme was observed for all the booths in the ESMO Exhibition area. The booths attracted a lot of footfall and were packed right from day 1 of the conference.  Most of the companies of our […]